Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAFE study: Stopping antibiotics after 3 days for the treatment of febrile neutropenia in haematology patients
2022-500389-84-00Phase 4Completed
- Sponsor
- UZ Leuven
- Start
- Aug 2023
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of imipenem, meropenem, cefepime, ceftazidime and piperacillin in febrile neutropenia (FN) (2 arms), sponsored by UZ Leuven. Primary endpoint: Primary endpoint: absence of serious medical complication (SMC) within 42 days. Started Aug 2023; status: completed.
02
Drugs
03
Conditions
febrile neutropenia (FN)
Beyond the preview
Go deeper on 2022-500389-84-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500389-84-00.